European Health IT Leaders Look to Denmark and Finland as Models for EHR Interoperability and Patient Access, Black Book Survey Reveals

Ahead of Next Week's HIMSS 25 Europe in Paris, Attendees Look to Top Interoperability Vendors for Solutions
PARIS, FRANCE / ACCESS Newswire / June 7, 2025 / Black Book Market Research today released findings from its latest survey highlighting the influence of Denmark and Finland on Electronic Health Record (EHR) interoperability and patient access initiatives across Europe. Conducted among 312 healthcare IT leaders from 8 higher tech-adoption European nations, the study underscores the strategic shift among healthcare organizations to emulate the advanced digital health ecosystems of these two Nordic frontrunners.
According to the survey, 94% of respondents identified Denmark's comprehensive national health portal, Sundhed.dk, as a model for delivering centralized patient records and seamless data exchange. Finland's Kanta platform similarly emerged as a key inspiration, cited by 90% of healthcare executives for its robust nationwide interoperability and extensive patient record accessibility.
The survey also recognized standout EHR technology vendors contributing significantly to these Nordic success stories. Epic Systems, utilized by major hospitals and health regions in Denmark, was ranked highly for its interoperability performance and scalability across diverse clinical environments. TietoEVRY and CGI, prominent in the Finnish healthcare market, received notable recognition for their roles in facilitating robust connectivity and patient-centric record management through Finland's Kanta service.
The report also highlighted Germany and Italy as the European nations with high EHR adoption rates yet struggling most significantly with interoperability and patient record access. Survey respondents identified primary reasons for these challenges as fragmented regional systems, lack of centralized governance, varying data standards, and insufficient investment in integrated digital health infrastructure. Providers in these countries reported an average interoperability satisfaction score of just 18%, significantly lower than Nordic benchmarks. According to respondents, responsibility for these challenges is shared: 86% cited government policy and funding issues, 21% pointed to vendor limitations in offering interoperable solutions, and 80% attributed the problems to provider reluctance or inability to implement cohesive digital strategies.
'European IT leaders are closely analyzing the strategic frameworks, governance structures, and advanced technology models pioneered by Denmark and Finland,' said Douglas Brown, founder of Black Book Market Research. 'Their proven success with interoperability standards, comprehensive EHR adoption, and seamless data integration is inspiring other European health systems to accelerate their digital transformations with secure data exchange and patient-centric solutions.'
Further survey insights highlighted specific adoption trends:
91% of surveyed executives emphasized the importance of centralized national infrastructures to enable seamless EHR integration.
84% noted the critical role of stringent data standardization, including widespread adoption of HL7 FHIR standards.
60% of respondents are now accelerating plans for patient-access portals inspired by the Danish and Finnish approaches.
'Denmark and Finland offer powerful examples of how cohesive digital health strategies improve patient care and operational efficiency,' added Brown. 'Vendors succeeding in these markets are proving vital to replicating these results throughout Europe.'
Top Client-Rated Interoperability Solutions Vendors at HIMSS 25 EU
Attendees of HIMSS25 Europe in Paris are encouraged to visit four leading interoperability vendors highly rated in recent Black Book IT user surveys across Europe. These vendors are recognized for their advanced solutions driving seamless connectivity, comprehensive data integration, and patient-centric interoperability. Each demonstrates notable success in enabling secure data exchange, facilitating real-time patient information access, and empowering healthcare organizations to optimize patient outcomes and operational efficiency. Visitors can expect compelling demonstrations highlighting the robust capabilities and proven successes these vendors have achieved within Europe's most digitally advanced healthcare environments:
About Black Book Market Research
Black Book Market Research is a leading global independent research firm providing unbiased, client-driven evaluations of healthcare technology and services. Black Book rankings are based entirely on user feedback and customer satisfaction data, offering strategic insights to healthcare providers, payers, vendors, and investors.
For more information, visit www.blackbookmarketresearch.com.
Contact InformationPress Office 8008637590
SOURCE: Black Book Research
press release

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

3 hours ago

• Bloomberg

UK Heat Wave Could Claim Nearly 600 Lives This Week, Experts Warn

Scientists have warned the elderly and other vulnerable groups in the UK are at risk of heat-related deaths this weekend, as a new study shows recent high temperatures could claim 570 lives in just over four days. Researchers at the London School of Hygiene & Tropical Medicine and Imperial College London published on Saturday a real-time analysis calculating the number of heat-related deaths expected from Thursday to Sunday.

Yahoo

5 hours ago

• Yahoo

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Vogue

7 hours ago

• Vogue

I Drank Beet Juice Every Day for a Month—It Had This Unexpected Effect

Disclaimer: I am a caffeine fiend. I drink so much coffee that my local barista regularly chides me, reminding me 'it's not good for your heart' to start the day with a triple-shot flat white before 6 a.m. But when I became pregnant—and had to limit my daily caffeine intake to around 200 mg a day (or two single-shot coffees)—it was a struggle to say the least. Pre-pregnancy, I also indulged in nootropics, Diet Coke, and caffeine-infused anything to help me get through the day. But now? It was all a no. And I was flat out tired. That's when I stumbled upon a juice called the 'Fatigue Fighter' made of beets, apples, oranges, celery, and ginger. I was willing to give basically anything a try, and quickly downed an entire container. Delicious. But it wasn't until my energy soared that I became a believer. Read on for all the reasons that maybe you should give it a try, too. What are the benefits of drinking beet juice? I've waxed lyrical about my personal experience with beet juice, but what are the actual health benefits? Evelina Sabonaityte, MD and clinical nutritionist, claims that beet juice is 'a nutrient-packed elixir.' Here are some of the benefits of beet juice, according to Evelina and Dr Katy Kasraie, one of the general practitioners at The London General Practice.